Boston Scientific Corp. shares fell 3.2% in pre-market trading to $48.25 after the medical device manufacturer disclosed a cybersecurity incident that disrupted global operations and limited order fulfillment.
The company, which operates in the $42.20 to $109.50 52-week range, said the incident occurred on August 25 and prompted the activation of incident response protocols alongside third-party cybersecurity specialists. The disruption affected the company’s ability to process and fulfill customer orders, though no further details on the scope or resolution timeline were provided.
Analysts at TD Cowen maintained a Buy rating with a $56 price target but noted that recent guidance reductions and cautious management commentary had led to sharp estimate cuts through 2027. Consensus revenue growth forecasts for 2027 were lowered to 4%, down from 8% prior to the second-quarter earnings report. Separately, Argus downgraded the stock to Hold, citing headwinds in the WATCHMAN and electrophysiology product lines.
The broader market showed limited movement, with the S&P 500 down 0.1% and the Nasdaq declining 0.2%.
